BioCentury | Jun 11, 2012
Company News

FDS Pharma, Opko deal

Opko will acquire a 45% stake in an undisclosed private Israeli company from FDS Pharma, which manufactures active pharmaceutical ingredients (APIs) for Russia and other markets. The Israeli company produces a third-generation HBV vaccine called...
BioCentury | Oct 24, 2011
Product Development

Alzheimer's rewind

...NASDAQ:THRX) TD-5108 Serotonin (5-HT4) receptor agonist Ph I AD pipeline: Antioxidation/anti-aggregation Company Product Description Status Scigenic Co. Ltd./Whanin...
BioCentury | Sep 1, 2008
Company News

Generex, Dong Sung sales and marketing update

Dong Sung received an exclusive, seven-year license to market and distribute Generex's Generex Oral-lyn insulin spray delivered via RapidMist technology in South Korea. SciGen Ltd. (ASX:SIE, Singapore), which previously received a non-exclusive license to market...
BioCentury | Apr 7, 2008
Company News

Generex, SciGen Ltd. sales and marketing update

SciGen received rights to market and distribute Generex's Generex Oral-lyn insulin spray delivered via RapidMist technology in China, Hong Kong, Indonesia, South Korea, Malaysia, the Philippines, Singapore, Thailand and Vietnam. SciGen will be responsible for...
BioCentury | Dec 24, 2007
Company News

NasVax, SciGen Ltd. deal

The companies will use NSVX's VaxiSome platform and SIE's hepatitis B antigen to develop and market an intranasal vaccine to treat HBV. The partners will split development costs and future revenues, starting with an Israeli...
BioCentury | Apr 10, 2006
Company News

SciGen Ltd., Shreya Group deal

The companies signed a memorandum of understanding under which SIE will acquire Shreya's GMP biological manufacturing facility in Pune, India. Shreya was previously SIE's contract manufacturer for biotech products. SciGen Ltd. (ASX:SIE), Singapore Shreya Group...
BioCentury | Nov 7, 2005
Company News

Bioton, SciTech Genetics Pte Ltd. deal

Bioton S.A. , Warsaw, Poland SciTech Genetics Pte Ltd. , Singapore Business: Gastrointestinal, Endocrine SciTech agreed to sell its 19.17% stake in SciGen Ltd. (ASX:SIE, Singapore) to Bioton. Bioton will purchase 105.7 million SIE shares from SciTech...
BioCentury | Dec 20, 2004
Company News

Intercell, SciGen Ltd. deal

Intercell and SIE will co-develop an HBV vaccine that combines SIE's Sci-B-Vac PreS1- and PreS2- HBV antigen with Intercell's Immunizer IC31 adjuvant. The companies will share development costs and will jointly own resulting products. Intercell...
BioCentury | Dec 13, 2004
Company News

Intercell, SciGen HBV vaccine deal

Intercell (Vienna, Austria) and SciGen (ASX:SIE) will co-develop an HBV vaccine that combines SIE's Sci-B-Vac PreS1- and PreS2- HBV antigen with Intercell's Immunizer IC31 adjuvant. The companies will share development costs and will jointly own...
BioCentury | Dec 11, 1995
Company News

Genetics Institute, SciGenics Inc. deal

GENIZ completed its tender offer for the 2.1 million SCGN shares outstanding at $14 per share (see BioCentury Oct. 16). SCGN is now a wholly owned subsidiary of GENIZ. Genetics Institute Inc. (GENIZ), Cambridge, Mass....
Items per page:
1 - 10 of 12
BioCentury | Jun 11, 2012
Company News

FDS Pharma, Opko deal

Opko will acquire a 45% stake in an undisclosed private Israeli company from FDS Pharma, which manufactures active pharmaceutical ingredients (APIs) for Russia and other markets. The Israeli company produces a third-generation HBV vaccine called...
BioCentury | Oct 24, 2011
Product Development

Alzheimer's rewind

...NASDAQ:THRX) TD-5108 Serotonin (5-HT4) receptor agonist Ph I AD pipeline: Antioxidation/anti-aggregation Company Product Description Status Scigenic Co. Ltd./Whanin...
BioCentury | Sep 1, 2008
Company News

Generex, Dong Sung sales and marketing update

Dong Sung received an exclusive, seven-year license to market and distribute Generex's Generex Oral-lyn insulin spray delivered via RapidMist technology in South Korea. SciGen Ltd. (ASX:SIE, Singapore), which previously received a non-exclusive license to market...
BioCentury | Apr 7, 2008
Company News

Generex, SciGen Ltd. sales and marketing update

SciGen received rights to market and distribute Generex's Generex Oral-lyn insulin spray delivered via RapidMist technology in China, Hong Kong, Indonesia, South Korea, Malaysia, the Philippines, Singapore, Thailand and Vietnam. SciGen will be responsible for...
BioCentury | Dec 24, 2007
Company News

NasVax, SciGen Ltd. deal

The companies will use NSVX's VaxiSome platform and SIE's hepatitis B antigen to develop and market an intranasal vaccine to treat HBV. The partners will split development costs and future revenues, starting with an Israeli...
BioCentury | Apr 10, 2006
Company News

SciGen Ltd., Shreya Group deal

The companies signed a memorandum of understanding under which SIE will acquire Shreya's GMP biological manufacturing facility in Pune, India. Shreya was previously SIE's contract manufacturer for biotech products. SciGen Ltd. (ASX:SIE), Singapore Shreya Group...
BioCentury | Nov 7, 2005
Company News

Bioton, SciTech Genetics Pte Ltd. deal

Bioton S.A. , Warsaw, Poland SciTech Genetics Pte Ltd. , Singapore Business: Gastrointestinal, Endocrine SciTech agreed to sell its 19.17% stake in SciGen Ltd. (ASX:SIE, Singapore) to Bioton. Bioton will purchase 105.7 million SIE shares from SciTech...
BioCentury | Dec 20, 2004
Company News

Intercell, SciGen Ltd. deal

Intercell and SIE will co-develop an HBV vaccine that combines SIE's Sci-B-Vac PreS1- and PreS2- HBV antigen with Intercell's Immunizer IC31 adjuvant. The companies will share development costs and will jointly own resulting products. Intercell...
BioCentury | Dec 13, 2004
Company News

Intercell, SciGen HBV vaccine deal

Intercell (Vienna, Austria) and SciGen (ASX:SIE) will co-develop an HBV vaccine that combines SIE's Sci-B-Vac PreS1- and PreS2- HBV antigen with Intercell's Immunizer IC31 adjuvant. The companies will share development costs and will jointly own...
BioCentury | Dec 11, 1995
Company News

Genetics Institute, SciGenics Inc. deal

GENIZ completed its tender offer for the 2.1 million SCGN shares outstanding at $14 per share (see BioCentury Oct. 16). SCGN is now a wholly owned subsidiary of GENIZ. Genetics Institute Inc. (GENIZ), Cambridge, Mass....
Items per page:
1 - 10 of 12